Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Translate Bio stock | 16.6

Own Translate Bio stock in just a few minutes.

Posted

Fact checked

Translate Bio, Inc is a biotechnology business based in the US. Translate Bio shares (TBIO) are listed on the NASDAQ and all prices are listed in US Dollars. Translate Bio employs 93 staff and has a trailing 12-month revenue of around USD$91.3 million.

How to buy shares in Translate Bio

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Translate Bio. Find the stock by name or ticker symbol: TBIO. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Translate Bio reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$16.6, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Translate Bio, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Translate Bio. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Translate Bio's share price?

Since the stock market crash in March caused by coronavirus, Translate Bio's share price has had significant positive movement.

Its last market close was USD$16.6, which is 52.47% up on its pre-crash value of USD$7.89 and 144.12% up on the lowest point reached during the March crash when the shares fell as low as USD$6.8.

If you had bought USD$1,000 worth of Translate Bio shares at the start of February 2020, those shares would have been worth USD$1,467.87 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$2,367.99.

Translate Bio share price

Use our graph to track the performance of TBIO stocks over time.

Translate Bio shares at a glance

Information last updated 2020-11-24.
Latest market close USD$16.6
52-week range USD$6.8 - USD$26.32
50-day moving average USD$15.0508
200-day moving average USD$15.9114
Wall St. target price USD$30.13
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.395

Buy Translate Bio shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Translate Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Translate Bio price performance over time

Historical closes compared with the close of $16.6 from 2020-11-16

1 week (2020-11-19) N/A
1 month (2020-10-30) 29.38%
3 months (2020-08-26) N/A
6 months (2020-05-26) N/A
1 year (2019-11-26) N/A
2 years (2018-11-26) N/A
3 years (2017-11-26) N/A
5 years (2015-11-26) N/A

Translate Bio financials

Revenue TTM USD$91.3 million
Gross profit TTM USD$-38,880,000
Return on assets TTM -4.28%
Return on equity TTM -23.49%
Profit margin -70.38%
Book value $4.925
Market capitalisation USD$1.4 billion

TTM: trailing 12 months

Shorting Translate Bio shares

There are currently 10.8 million Translate Bio shares held short by investors – that's known as Translate Bio's "short interest". This figure is 0.3% up from 10.8 million last month.

There are a few different ways that this level of interest in shorting Translate Bio shares can be evaluated.

Translate Bio's "short interest ratio" (SIR)

Translate Bio's "short interest ratio" (SIR) is the quantity of Translate Bio shares currently shorted divided by the average quantity of Translate Bio shares traded daily (recently around 897016.98425849). Translate Bio's SIR currently stands at 12.07. In other words for every 100,000 Translate Bio shares traded daily on the market, roughly 12070 shares are currently held short.

However Translate Bio's short interest can also be evaluated against the total number of Translate Bio shares, or, against the total number of tradable Translate Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Translate Bio's short interest could be expressed as 0.15% of the outstanding shares (for every 100,000 Translate Bio shares in existence, roughly 150 shares are currently held short) or 0.3072% of the tradable shares (for every 100,000 tradable Translate Bio shares, roughly 307 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Translate Bio.

Find out more about how you can short Translate Bio stock.

Translate Bio share dividends

We're not expecting Translate Bio to pay a dividend over the next 12 months.

Translate Bio share price volatility

Over the last 12 months, Translate Bio's shares have ranged in value from as little as $6.8 up to $26.32. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Translate Bio's is 0.3289. This would suggest that Translate Bio's shares are less volatile than average (for this exchange).

Translate Bio overview

Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site